Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Yemaachi Biotechnology
AddedMar 17, 2024
UpdatedJul 1, 2026
Yemaachi Biotechnology

Yemaachi Biotechnology

Seed

Expanding precision cancer solutions in Africa through genetic diversity.

Founded
2020
Accelerator
Y Combinator logoY CombinatorS21
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to diversify and expand access to precision cancer diagnostics and therapeutics, Yemaachi Biotechnology focuses on leveraging the genetic diversity of African populations. By collecting and sequencing samples from across Africa, Yemaachi aims to optimize existing diagnostic tests and aid in the discovery of new ones. Their core services include advanced cancer diagnostics and research-driven solutions tailored to the unique genetic makeup of African populations, addressing a critical gap in global healthcare.

Notable figures affiliated with Yemaachi include experts in oncology and genomics, contributing to its robust research agenda. The company has garnered attention for its innovative approach and has been involved in significant initiatives such as the AfriCAN Webinar series. Yemaachi's key achievements include pioneering research that enhances the understanding of cancer in genetically diverse populations, thereby impacting global precision oncology. Their work is instrumental in developing more effective cancer treatments and diagnostics, particularly for underrepresented groups.

Yemaachi Biotechnology - Quick Facts

When was Yemaachi Biotechnology founded?

Yemaachi Biotechnology was founded in 2020.

When was Yemaachi Biotechnology's last funding round?

Yemaachi Biotechnology's most recent funding round was for $125k (USD) in January 2021.

How much has Yemaachi Biotechnology raised to-date?

As of Jan 1, 2021, Yemaachi Biotechnology has raised a total of $125k (USD).

How many employees does Yemaachi Biotechnology have?

Yemaachi Biotechnology has 16 employees as of Aug 23, 2023.

Yemaachi Biotechnology - Classification

Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Diagnostics
Tags
  • Biotech